经PCS联合灌注羟基喜树碱在中晚期肝脏肿瘤治疗中的应用研究  

Clinical Application of Implantable Portacatheter System via Femoral Artery in Treatment of Advanced Hepatic Carcinoma

作　　者：张福君[1] 吴沛宏[1] 杨柳明[2] 范卫君[1] 黄金华[1] 陈洪胜 宝金良 

机构地区：[1]中山医科大学肿瘤医院影像介入科,广州市510060 [2]广东省廉江市医院消化科 [3]广东省顺德市桂洲医院放射科

出　　处：《中国肿瘤临床》2000年第12期912-14,共1页Chinese Journal of Clinical Oncology

摘　　要：目的：探讨应用经皮股动脉穿刺导管药盒植入系统PCS对晚期恶性肿瘤进行介入治疗的可行性、临床疗效、并发症及处理。方法：经股动脉穿刺植入PCS至肝靶血管，经PCS化疗灌注和或化疗栓塞治疗，其中原发性肝癌25例，转移性肝癌17例，每4～6周为一疗程。结果：45例患者经PCS治疗后生存期6～20个月，中位生存期13个月，有效率CR＋PR66．6％（30／45）。并发症有留置管滑脱2例，留置管移位2例切口裂开1例，药盒植入部位组织坏死1例。全组病例未发生感染、出血等并发症及导管堵塞现象。结论：经皮股动脉导管药盒植入术安全、有效，植入简便、安全，适宜于晚期肿瘤的治疗。Objective To discuss the feasibility clinical effect complications and disposal of complications using implantable porta－catheter system PCS via femoral artery for the inventional treatment of advanced malignant hepatic tumor． Methods Forty－five cases of advanced hepatic tumor including primary hepatic carcinoma 28 metastatic hepatic carcinoma 17 were treated by chemotherapeutic infusion and／or chemoembolization through PCS and 4~6 weeks was a course of therapy． Results The survival period of 45 patients was 6~20 months after chemotherapeutic infusion of PCS． The mean survival period was 13 months and the effective rate CR＋PR was 66．7％30／45． The complications included the tip of catheter dislocating into abdominal aorta 2 into common bile duct 1 and into gastro－duodenal artery 1． One case complicated by disrupture of wound and 1 case of non－bacterial chemical necrosis at the site of PCS． No local infectionhemorrhage and catheter obstruction were observed． Conclusion Implantation of PCS through femoral artery is safe effective and suitable for the treatment of advanced malgnant hepatic tumors

关 键 词：肝脏肿瘤 药盒导管植入系统 羟基喜树碱 

分 类 号：R735.7[医药卫生—肿瘤] R730.5[医药卫生—临床医学]